The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

Publications

van Eeden R, Rapoport BL, Smit T, Anderson R

Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review.

Frontiers in oncology. 2019;9:659

Elkington PT, Bateman AC, Thomas GJ, Ottensmeier CH

Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.

American journal of respiratory and critical care medicine. 2018;198(11):1451-1453

Fujita K, Terashima T, Mio T

Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(12):2238-2240